Study on the sensitizing effect of SCR7 on cisplatin chemotherapy in triple-negative breast cancer

Qi Ye; Pan Haiting; Wang Xiumei

doi:10.13406/j.cnki.cyxb.003166

您当前的位置：

首页 >

文章列表页 >

Study on the sensitizing effect of SCR7 on cisplatin chemotherapy in triple-negative breast cancer

Clinical study | 更新时间：2025-10-21

- Study on the sensitizing effect of SCR7 on cisplatin chemotherapy in triple-negative breast cancer
- Journal of Chongqing Medical University Vol. 48, Issue 2, Pages: 220-225(2023)
- 作者机构：
  
  1.内蒙古医科大学附属人民医院肿瘤内科，呼和浩特 010010
  2.内蒙古医科大学基础医学院免疫学教研室，呼和浩特 010050
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003166
  CLC： 737.9
- Received：10 June 2022，
  
  Revised：2022-06-21，
  
  Accepted：24 August 2022，
  
  Published：28 February 2023
- 稿件说明：
移动端阅览
祁冶,潘海婷,王秀梅.SCR7对三阴性乳腺癌顺铂化疗的增敏作用研究[J].重庆医科大学学报,2023,48(2):220-225.

Qi Ye,Pan Haiting,Wang Xiumei.Study on the sensitizing effect of SCR7 on cisplatin chemotherapy in triple-negative breast cancer[J].Journal of Chongqing Medical University,2023,48(2):220-225.
祁冶,潘海婷,王秀梅.SCR7对三阴性乳腺癌顺铂化疗的增敏作用研究[J].重庆医科大学学报,2023,48(2):220-225. DOI： 10.13406/j.cnki.cyxb.003166.

Qi Ye,Pan Haiting,Wang Xiumei.Study on the sensitizing effect of SCR7 on cisplatin chemotherapy in triple-negative breast cancer[J].Journal of Chongqing Medical University,2023,48(2):220-225. DOI： 10.13406/j.cnki.cyxb.003166.

摘要

目的

探讨SCR7对三阴性乳腺癌顺铂化疗的增敏作用。

方法

选用三阴乳腺癌MDA-MB-231细胞分为空白对照组、10 μmol/L顺铂对照组和联合组（10 μmol/L顺铂+10、20和40 μmol/L SCR7），采用CCK-8法检测细胞活性并计算细胞增殖抑制率；取对数期TNBC MDA-MB-231细胞构建三阴性乳腺癌移植瘤小鼠模型，建模成功后荷瘤裸鼠随机分为对照组、SCR7组，顺铂组、SCR7+顺铂组；饲养24 d后，观察比较各组荷瘤鼠肿瘤质量、瘤体体积的变化，计算肿瘤抑制率；苏木精-伊红（hematoxylin-eosin，HE）染色观察瘤体组织细胞形态学变化；原位末端标记法（

in situ

end labeling，TUNEL）检测乳腺癌肿瘤组织的凋亡；采用Western blot检测X射线修复交叉互补蛋白1（X-ray repair cross complementing 1，XRCC1）、多聚（ADP核糖）聚合酶1[poly（adp ribose） polymerase 1，PARP1

]

蛋白表达。

结果

联合组细胞增殖抑制率均高于对照组（

0.05），且随SCR7质量浓度增大呈逐渐升高趋势（

0.05）。体内动物实验发现：相较于对照组，SCR7组、顺铂组、SCR7+顺铂组中的乳腺癌肿瘤体积、瘤重减小（

0.05），其肿瘤抑制率分别是32%、40%、81%；SCR7+顺铂组较顺铂组减少更明显（

0.05），且小鼠体质量与SCR7组、顺铂组相比无明显差异（

0.05）；HE染色观察干预组肿瘤组织均呈现明显形态学改变，其中SCR7+顺铂组肿瘤细胞退变变化最明显；TUNEL染色显示SCR7+顺铂组肿瘤细胞凋亡最为严重，可见大量红色细胞凋亡；Western blot检测发现，SCR7+顺铂组XRCC1、PARP1蛋白表达均明显低于其他组，差异均有统计学意义（

0.05）。

结论

SCR7在体内外对三阴乳腺癌顺铂化疗均有增敏作用。

Abstract

Objective

To investigate the sensitizing effect of SCR7 on cisplatin chemotherapy in triple-negative breast cancer（TNBC）.

Methods

MDA-MB-231 cells of TNBC were selected and divided into blank control group，10 μmol/L cisplatin control group and combined group（10 μmol/L cisplatin + 10，20 and 40 μmol/L SCR7）. CCK-8 method was used to detect cell activity and calculate cell proliferation inhibition rate. A TNBC mice model was constructed by using TNBC MDA-MB-231 cells. The nude mice were randomly divided into control group，SCR7 group，cisplatin group and SCR7+cisplatin group. After 24 days of feeding，the changes of mass and tumor volume of tumor-bearing mice in all groups were observed and compared，and the tumor inhibition rate was calculated. Morphological changes of tumor cells were observed by hematoxylin - eosin（HE） staining. The apoptosis of tumor cells was detected by

in situ

end labeling（TUNEL） method，and the expressions of X-ray repair cross complementing 1（XRCC1） and poly（ADP-ribose） polymerase 1（PARP1） proteins were detected by Western blot.

Results

The cell proliferation inhibition rate in the combined group was higher than that in the control group（

0.05），and it wasgradually increased with the increase of SCR7 concentration（

0.05）. Animal experiments

in vivo

found：compared with the control group，the tumor volume and tumor weight of breast cancer in SCR7 group，cisplatin group and SCR7+cisplatin group decreased（

0.05），and the tumor inhibition rates were 32%，40% and 81%，respectively. The SCR7+cisplatin group showed a more significant reduction than SCR7 group and cisplatin group（

0.05），but there was no significant difference in mouse body weight compared to the cisplatin group（

0.05）. The tumor tissues in the intervention gro

ups showed obvious morphological changes by HE staining，among which the tumor cells in the SCR7+cisplatin group showed the most obvious degenerative changes. TUNEL staining showed that the tumor cells in the SCR7+cisplatin group had the most serious apoptosis，and a large number of red apoptotic cells were seened. Western blotting showed that the protein expressions of XRCC1 and PARP1 in SCR7+cisplatin group were significantly lower than those in other groups，and the differences were statistically significant（

0.05）.

Conclusion

SCR7 has sensitizing effect on cisplatin chemotherapy for TNBC

in vivo

and

in vitro

关键词

Keywords

references

Lee JS ， Yost SE ， Yuan Y . Neoadjuvant treatment for triple negative breast cancer：recent progresses and challenges [J ] . Cancers ， 2020 ， 12 （ 6 ）： 1404 .

廖雪莲，曾　育，王小毅 . PSME3-NF-κB途径介导三阴性乳腺癌的侵袭与转移 [J ] . 重庆医科大学学报， 2019 ， 44 （ 2 ）： 169 - 176 .

Liao XL ， Zeng Y ， Wang XY . Invasion and metastasis of triple-negative breast cancer mediated by the PSME3-NF-κB pathway [J ] . J Chongqing Med Univ ， 2019 ， 44 （ 2 ）： 169 - 176 .

Huang J ， Liu C ， Duan S ， et al . Gigantol inhibits proliferation and enhances DDP-induced apoptosis in breast-cancer cells by downregulating the PI3K/Akt/mTOR signaling pathway [J ] . Life Sci ， 2021 ， 274 ： 119354 .

Spiegel JO ， Van Houten B ， Durrant JD . PARP1：structural insights and pharmacological targets for inhibition [J ] . DNA Repair (Amst) ， 2021 ， 103 ： 103125 .

Pan JW ， Huang G ， Yin ZY ， et al . Circular RNA FLNA acts as a sponge of miR-486-3p in promoting lung cancer progression via regulating XRCC1 and CYP1A1 [J ] . Cancer Gene Ther ， 2022 ， 29 （ 1 ）： 101 - 121 .

Ray U ， Vartak SV ， Raghavan SC . NHEJ inhibitor SCR7 and its different forms：promising CRISPR tools for genome engineering [J ] . Gene ， 2020 ， 763 ： 144997 .

Manjunath M ， Choudhary B ， Raghavan SC . SCR7，a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end-joining [J ] . Cancer Rep（Hoboken）， 2021 ， 4 （ 3 ）： e1341 .

Yang MD ， Sun Y ， Zhou WJ ， et al . Resveratrol enhances inhibition effects of cisplatin on cell migration and invasion and tumor growth in breast cancer MDA-MB-231 cell models in vivo and in vitro [J ] . Molecules ， 2021 ， 26 （ 8 ）： 2204 .

Wakita M ， Takahashi A ， Sano O ， et al . A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells [J ] . Nat Commun ， 2020 ， 11 （ 1 ）： 1935 .

Gkotzamanidou M ， Terpos E ， Bamia C ， et al . DNA repair of myeloma plasma cells correlates with clinical outcome：the effect of the nonhomologous end-joining inhibitor SCR7 [J ] . Blood ， 2016 ， 128 （ 9 ）： 1214 - 1225 .

Kumar A ， Bhatkar D ， Jahagirdar D ， et al . Non-homologous end joining inhibitor SCR-7 to exacerbate low-dose doxorubicin cytotoxicity in HeLa cells [J ] . J Cancer Prev ， 2017 ， 22 （ 1 ）： 47 - 54 .

Causse SZ ， Marcion G ， Chanteloup G ， et al . HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells [J ] . Oncogene ， 2019 ， 38 （ 15 ）： 2767 - 2777 .

Hu Z ， Shi ZY ， Guo XG ， et al . Ligase IV inhibitor SCR7 enhances gene editing directed by CRISPR-Cas9 and ssODN in human cancer cells [J ] . Cell Biosci ， 2018 ， 8 ： 12 .

Kopa P ， Macieja A ， Pastwa E ， et al . DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma（LoVo）cells [J ] . Mol Biol Rep ， 2021 ， 48 （ 1 ）： 709 - 720 .

Ghosh R ， Roy S ， Kamyab J ， et al . Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways [J ] . DNA Repair ， 2016 ， 45 ： 56 - 62 .

孙建兵，吴海龙，唐　璇，等 . XRCC 1基因在乳腺癌中表达的临床意义及其细胞与分子机制 [J ] . 肿瘤， 2019 ， 39 （ 1 ）： 30 - 40 .

Sun JB ， Wu HL ， Tang X ， et al . Clinical significance of XRCC1 gene expression in human breast cancer and its cell and molecular mechanisms [J ] . Tumor ， 2019 ， 39 （ 1 ）： 30 - 40 .

刘芃菲，卓钟灵，刘　畅，等 . 乳腺癌多通路基因检测及突变情况分析 [J ] . 中华检验医学杂志， 2021 ， 44 （ 5 ）： 394 - 401 .

Liu PF ， Zhuo ZL ， Liu C ， et al . Detection of multi-pathway genes and analysis of gene mutations in breast cancer [J ] . Chin J Lab Med ， 2021 ， 44 （ 5 ）： 394 - 401 .

Xiong A ， Gokyer D ， Shapiro-Franklin N ， et al . The role of AKT and NHEJ pathways in the sensitivity of BRCA2-mutated epithelial ovarian cancer to PARP inhibitors [J ] . Gynecol Oncol ， 2020 ， 159 ： 146 .

Park Y ， Chui MH ， Suryo Rahmanto Y ， et al . Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy [J ] . Clin Cancer Res ， 2019 ， 25 （ 18 ）： 5584 - 5594 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of miR-145 targeting ADAM17 on the growth of triple-negative breast cancer xenografts in nude mice and associated mechanism

Investigation on the mechanism of action of Mailuoning in the treatment of acute kidney injury using network pharmacology

Effect of Glycyrrhiza uralensis Fisch. endophytes combined with cisplatin on proliferation and apoptosis of A549 cells

Inhibitory effect of dihydroartemisinin combined with cisplatin on the proliferation of bladder cancer cells

Related Author

Yan Li

Hu Baoshan

Shang Hongzhou

Zhang Xuepeng

Yang Guannan

Miao Yaning

Chen Bonian

Yan Jiamin

Related Institution

School of Materials Science and Engineering，North China University of Science and Technology

Department of Surgical Oncology，The Affiliated Hospital of North China University of Science and Technology

Clinical Research Laboratory Center of Affiliated Hospital of Guangdong Medical University

Department of Respiratory Medicine，Affiliated Hospital of Guangdong Medical University

Department of Anesthesiology，Affiliated Hospital of Guangdong Medical University

⁰